ClinicalTrials.gg
TerminatedNCT05200364Updated Sep 22, 2025

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

A Phase 1 interventional study of STRO-002 and Bevacizumab in Ovarian Cancer, Ovarian Carcinoma and Ovary Cancer, sponsored by Sutro Biopharma, Inc.. Terminated at 6 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Sutro Biopharma, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Terminated Early

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 275 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
655th of 1,499
58 · median 47
Started
2022
with 75 others
Phase 1
548 of 1,780
73 open now
Registered
1,427th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 655th largest by enrollment of the 1,499 interventional ones that give a count, is one of 76 that started in 2022, is one of 548 in phase 1, and was the 1,427th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

275 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Read the detailed description

This study is a Phase 1, open-label, multicenter, dose escalation study to assess preliminary efficacy for STRO-002 combined with bevacizumab in patients with advanced ovarian cancer that is refractory or has relapsed after standard available therapy. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this study.

The dosing regimen will include bevacizumab administered at the labeled dose of 15 mg/kg IV q 3 weeks given together with STRO-002 at increasing dose levels administered IV q 3 weeks. The RP2D of STRO-002 given with bevacizumab 15 mg/kg q 3 weeks will be determined by dose escalation.

Dose expansion will enroll approximately 40 subjects with advanced relapsed ovarian cancer treated with STRO-002 plus bevacizumab at the RP2D determined in dose escalation. Subjects in the dose expansion portion of the study will be required at screening to submit both archival tumor tissue (if available and available tissue has adequate tumor) and tumor tissue from a biopsy done during screening to the central laboratory for analysis of FOLRα expression, both prior to enrollment in the study.

03

Conditions studied

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovary Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. 0-1
  3. > 3 months
  4. High Grade serous epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer with pathology report documentation of tumor type.
  5. At least one measurable target lesion per v1.1.
  6. Tumor tissue for FolRα expression testing prior to enrollment.

    1. For dose escalation: tissue may be from either or from a biopsy performed during screening.
    2. For dose expansion part of the study, tissue from both archival tumor tissue and a biopsy performed during screening is required.
  7. Adequate bone marrow function defined as:

    1. (ANC) ≥1500/μL
    2. ≥ 9g/dL
    3. count ≥ 100 x 10\^3/μL
  8. Adequate liver function defined as:

    1. and AST \< 2.5 x
    2. ALP \< 2.5 x ULN
    3. \< 1.5 x ULN
  9. Adequate renal function defined as serum creatinine ≤ 1.5 x ULN or (CrCl) > 40 mL/min.

    Subjects enrolling into Dose Escalation must also meet the following inclusion criteria:

  10. and/or PD on last treatment regimen and one of the following:

    1. Primary Platinum refractory and received no more than 1 prior regimen
    2. Primary platinum resistant and received no more than 4 prior regimens
    3. Platinum sensitive and all of the following:

      • received at least 2 platinum-based therapies or received 1 platinum and 1 non-platinum based therapy (if unable to receive a second platinum regimen due to toxicity) or received at least 1 platinum-based therapy (if the regimen contained a PARP inhibitor given as maintenance treatment)
      • received no more than 1 additional regimen after becoming platinum resistant
      • received no more than 4 prior regimens

    Subjects enrolling into Part 2, Dose Expansion must also meet the following inclusion criteria:

  11. Relapsed and/or PD on last treatment regimen and one of the following:

    1. Platinum resistant and received no more than 4 prior regimens
    2. Platinum sensitive and

      • received at least 2 platinum-based therapies or received 1 platinum and 1 non-platinum based therapy (if unable to receive a second platinum regimen due to toxicity) or received at least 1 platinum-based therapy (if the regimen contained a PARP inhibitor given as maintenance treatment)
      • received no more than 1 additional regimen after becoming platinum resistant
      • received no more than 4 prior regimens

Exclusion criteria

Exclusion Criteria:

  1. Low grade ovarian carcinoma (Grade 1).
  2. Clear cell, mucinous, endometrioid, sarcomatous, and mixed histology ovarian carcinomas, endometrial leiomyosarcoma, and endometrial stromal sarcomas.
  3. Prior treatment with an ADC with a tubulin inhibitor warhead.
  4. Prior treatment with other FolRα targeting agents unless approved by a Sutro medical monitor or designee.
  5. Subjects who are primary platinum- during frontline treatment are excluded from the Expansion Cohort (Allowed in Dose Escalation if no more than 1 prior regimen).
  6. Greater than 4 (> 1 prior if primary platinum refractory).
  7. Any prior toxicity that required permanent discontinuation of bevacizumab or other to receive bevacizumab per institutional guidelines.
  8. Previous solid organ transplantation.
  9. Current signs/symptoms of bowel obstruction and/or signs/symptoms of or bowel obstruction within 3 months of initiation of study treatment.
  10. Grade ≥2 toxicity from prior anticancer therapy with the exception of Grade 2 alopecia or Grade 2 neuropathy.
  11. Uncontrolled hypertension
  12. Sensory or motor neuropathy Grade > 1 at screening prior to initiation of study treatment.
  13. Potentially fatal concurrent or recent . Subjects with past or current malignancy need to be discussed with the sponsor to determine eligibility.
  14. Chronic or ongoing active infection requiring systemic treatment.
  15. Ongoing therapy, including systemic . Note: Physiologic replacement and use of topical or inhaled corticosteroids are allowed. Dexamethasone may be used to treat chemotherapy induced nausea per institutional guidelines.
  16. cardiac disease.
  17. History or clinical signs of meningeal or active central nervous system involvement.
  18. Known severe or asthma
  19. Active pneumonitis within 6 months of initiating study treatment.
  20. History of stroke or history of significant cerebrovascular disease (i.e., ) within 6 months of initiation of study treatment.
  21. History of pulmonary embolism or any Grade 3 thromboembolic event within 6 months of initiation of study treatment.
  22. Known seropositivity.
  23. Active or and positive serology (unless due to vaccination or passive immunization due to immunoglobulin therapy) with the following exceptions:

    1. Subject has had HCV but received antiviral treatment and shows no detectible HCV viral DNA for 6 months prior to screening
    2. Subject has had HBV but is HBV surface antigen (HBsAg) and viral DNA negative at screening
    3. Subject has had HBV but received antiviral treatment and have undetectable viral DNA for 6 months prior to screening
  24. Concurrent participation in another therapeutic treatment trial
  25. Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
  26. Females who are pregnant or breastfeeding, and all women of unwilling to use adequate barrier while on treatment and for 16 weeks after last dose of STRO-002/bevacizumab and 6 months after the last dose of bevacizumab.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Experimental :STRO-002 treatment in combination with Bevacizumab

    Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg

    Drug: STRO-002 · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy

    Incidence and severity of adverse events (AEs) and clinical laboratory abnormalities observed across STRO-002/bevacizumab dose levels. Incidence of dose-limiting toxicities (DLTs) through Day 1-21 following administration of each initial STRO-002/bevacizumab dose.

    Time frame: From baseline through end of study (approximately 24 months)

  2. Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumab

    Frequency of DLTs across STRO-002 dose levels

    Time frame: From baseline through end of study (approximately 24 months)

Secondary outcomes

  1. Part 1 - Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax).

    Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002

    Time frame: From baseline through end of study (approximately 24 months)

  2. Part 1 - Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)

    Measurement of AUC

    Time frame: From baseline through end of study (approximately 24 months)

  3. Part 1 - Assess the formation of anti-drug antibodies (ADAs) to STRO-002 when administered with bevacizumab.

    Circulating ADAs formed to STRO-002

    Time frame: From baseline through end of study (approximately 24 months)

07

Study locations

6 sites
  • University of South Florida,
    Tampa, Florida 33612, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19017, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Li X, Zhou S, Abrahams CL, Krimm S, Smith J, Bajjuri K, Stephenson HT, Henningsen R, Hanson J, Heibeck TH, Calarese D, Tran C, Yin G, Stafford RL, Yam AY, Kline T, De Almeida VI, Sato AK, Lupher M, Bedard K, Hallam TJ. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167. doi: 10.1158/1535-7163.MCT-22-0322. PubMed 36459691 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jun 2025, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2021
First posted
Jan 20, 2022
StartActual
Mar 22, 2022
Primary completionActual
Jun 1, 2025
CompletionActual
Jun 1, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05200364
Lead sponsor
Sutro Biopharma, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Mar 22, 2022
Primary completion
Jun 1, 2025
Completion
Jun 1, 2025
Last update
Sep 22, 2025

Study contacts

Arturo Molina, MD
study chair · Sutro Biopharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luveltamab tazevibulin

Start the discussion